TNKS and hepatocellular carcinoma: Using the reporter assay, we confirmed that tankyrase inhibitors, XAV939 and IWR-1, reduced Wnt pathway activity in human HCC cell lines HuH7 (Figs. 1A-B) and Hep3B (Figs. 1C-D).